At the news
? BULLISHIMPACT 7/10 6-K filed Apr 21, 2026 at 10:40 ET
Immatics announced that four abstracts from its clinical programs will be presented as oral presentations at the 2026 ASCO Annual Meeting, including Phase 1b data for anzu-cel in melanoma, updated data for IMA203CD8 in gynecologic cancers, and first-in-human results for IMA401. This confirms scientific validation and visibility for its PRAME and MAGEA4/8-targeted therapies.
- Four oral presentations accepted at ASCO 2026, a top oncology conference
- Data includes Phase 1b results for anzu-cel in advanced melanoma and uveal melanoma
- Updated Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
- Updated Phase 1 data for PRAME cell therapy in synovial sarcoma
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access